Skip to main content

Table 1 Liver attenuation and liver enzymes by steatosis/steatohepatitis status

From: Immune checkpoint inhibitors and their impact on liver enzymes and attenuation

  Overall (n = 81) Steatosis/Steatohepatitis
Liver attenuation (HU)   Yes (n = 11) No (n = 70) p value – Between groups
Baseline 58.44 46.67 60.29  < 0.001*
Post-treatment 60.60 54.83 61.51 0.460
∆ Post-treatment/Baseline 2.17 8.16 1.22 0.165
p value – ∆ Post-treatment/Baseline 0.055 0.103 0.247 -
  Overall (n = 101) Steatosis/Steatohepatitis
Liver enzymes (AST)   Yes (n = 31) No (n = 70) p value – Between groups
Baseline 27.57 37.74 23.07 0.003*
Post-treatment 22.92 26.35 21.40 0.014
Last follow up 26.12 31.19 23.40 0.057
∆ Post-treatment/Baseline -4.75 -11.39 -1.67 0.044
p value – ∆ Post-treatment/Baseline 0.005* 0.018 0.114 -
  Overall (n = 101) Steatosis/Steatohepatitis
Liver enzymes (ALT)   Yes (n = 31) No (n = 70) p value – Between groups
Baseline 28.76 45.52 21.34 0.007*
Post-treatment 24.20 32.03 20.73 0.009*
Last follow up 25.28 28.13 24.03 0.332
∆ Post-treatment/Baseline -4.75 -13.48 -0.61 0.093
p value – ∆ Post-treatment/Baseline 0.076 0.073 0.710 -
  1. Note. Statistical comparisons were conducted with independent t-tests for intergroup comparisons and paired t-tests for intragroup comparisons. HU Hounsfield unit
  2. *Statistically significant at p < 0.05/k (k = number of tests performed) after Bonferroni correction for multiple testing